|Forbion Capital partners||General partner||Germany|
Where will European pre-seed, seed and Series A funding go in 2018?
Holger Reithinger holds a PhD in Biochemistry, which he obtained under the supervision of Prof. Dr. Arne Skerra; all in the department of Prof. Dr. Hartmut Michel (Nobel Laureate 1988) at the Max-Planck-Institute of Biophysics. As an undergraduate, Holger studied Molecular Biology/ Microbial Biology and Biochemistry at the Universities of Heidelberg and Munich. After his studies, Holger gained operational experience as a product development manager at Biometra/ Whatman Plc (now part of GE Healthcare). He started his career in Venture Capital in 1997 as an Investment Manager at Technologieholding VC GmbH which at that time was one of the leading German Venture Capital firm. Technologieholding was acquired by the 3i Group in early 2000, where Holger became a Director at its Germany’s healthcare practice. Following this assignment, he became Principal and later Partner at Global Life Science Ventures, a well-established life sciences-focused partnership with offices in Switzerland and Germany. Holger has served on the Boards of numerous life sciences companies including Epigenomics (IPO 2004), MBT (assets sold to Medigene AG), 4SC (IPO 2005), NeurogesX (IPO 2007), Fibrex Medical (assets licensed to Ikaria Inc.), Agendia BV, Santaris A/S (sold to Roche 2014) and Rigontec GmbH (sold to MSD 2017). Holger holds board seats at Curetis NV (IPO 2015), Cellnovo Group S.A. (IPO 2015), Allecra Therapeutics GmbH and catalYm GmbH.